Thermal and Mountain Medicine Division, United States (U.S.) Army Research Institute of Environmental Medicine, Natick, MA, United States.
Office of the Senior Scientist, United States (U.S.) Army Research Institute of Environmental Medicine, Natick, MA, United States.
Front Endocrinol (Lausanne). 2024 Aug 1;15:1444568. doi: 10.3389/fendo.2024.1444568. eCollection 2024.
The Food and Drug Administration's (FDA) obesity drug guidance is set on the basis of body mass index (BMI), with thresholds of either BMI ≥30 or BMI ≥27 kg/m with weight-related comorbidities. While BMI is associated with obesity-related health outcomes, there are known limitations to use as a direct measure of body fat or metabolic health, and the American Medical Association has highlighted limitations of BMI in assessing individual obesity risks. BMI thresholds impose a barrier to treatment. In a sample from the NHANES dataset (n=6,646 men and women), 36% of individuals with metabolic syndrome (MetS) may not be eligible for obesity pharmacotherapy. This analysis provides quantifiable justification for refinement of the BMI treatment criteria with a more holistic assessment of individual obesity-related disease risk.
美国食品和药物管理局（FDA）的肥胖药物指南是基于身体质量指数（BMI）制定的，标准为 BMI≥30 或 BMI≥27kg/m 并伴有与体重相关的合并症。虽然 BMI 与肥胖相关的健康结果有关，但作为体脂或代谢健康的直接衡量标准，它存在已知的局限性，美国医学协会已经强调了 BMI 在评估个体肥胖风险方面的局限性。BMI 阈值为治疗设置了障碍。在 NHANES 数据集的一个样本中（n=6646 名男性和女性），有 36%的代谢综合征（MetS）患者可能不符合肥胖症药物治疗的条件。这项分析为更全面地评估个体肥胖相关疾病风险，对 BMI 治疗标准进行细化提供了量化依据。
